Meeting
2015 Gastrointestinal Cancers Symposium
Colorectal cancer (CRC) cohort analysis of patients treated with buparlisib in a distinctive tissue-agnostic trial model for molecularly preselected tumors.
Authors
Sarina Anne Piha-Paul
The University of Texas MD Anderson Cancer Center, Houston, TX
Sarina Anne Piha-Paul , James A. Knost , Petros Nikolinakos , Lee Steven Schwartzberg , Denise A. Yardley , Eric Daniel Slosberg , Barinder Kang , Theresa White , Claudia Lebedinsky
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01833169
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 644)
DOI
10.1200/jco.2015.33.3_suppl.644
Abstract #
644
Poster Bd #
C36
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.
First Author: Sarina Anne Piha-Paul
Poster
2022 ASCO Annual Meeting
Racial differences in the mutational landscape of serous endometrial cancer.
First Author: Julian C. Schink
Poster
2014 Gastrointestinal Cancers Symposium
Next-generation sequencing yields promising targets in advanced cholangiocarcinoma (CCA).
First Author: Rachna T. Shroff
Poster
2024 ASCO Genitourinary Cancers Symposium
Comprehensive analysis of targetable alterations in urachal cancer by NGS.
First Author: David Joseph Benjamin